Blood-brain barrier permeability and cerebral perfusion in Alzheimer*s disease

Blood-brain barrier permeability and cerebral perfusion in Alzheimer*s disease - Vascular dysfunction in AD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38302

Enrollment

Registered

2011-07-20

Start date

2011-09-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodegeneratieve aandoeningen Alzheimer's disease dementia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with AD: • Informed consent before participation in the study • Received standard diagnostic procedure according to the Parelsnoer Initiative procedure • Diagnosed with dementia of the Alzheimer*s type • Clinical dementia rating (CDR) of 1, which means a mild to moderate stage of dementia • MMSE >= 20 and patients are mentally competent This inclusion criterion is conform the Parelsnoer Initiative inclusion criteria. By the Parelsnoer Initiative, individuals with an MMSE >=18 are considered mentally competent.;Patients with prodromal AD: • Informed consent before participation in the study • Received standard diagnostic procedure according to the Parelsnoer Initiative procedure • Diagnosis of prodromal dementia according to the Dubois criteria (16) • CDR of 0.5, which suggests a very mild stage of dementia • Memory impairment defined as Delayed Recall on Verbal Learning Test (15 WLT) = 20 and patients are mentally competent. • Medial temporal lobe atrophy scale MTA >= 1 (17) OR abnormal levels of Aß42, t-tau or p-tau;Healthy participants: • Informed consent before participation in the study • No Diagnosis of dementia, prodromal dementia, or mild cognitive impairment. • MMSE >= 26 • No substantial memory complaints (according to participant ánd partner/relative) • Age, gender and education is matched to the patient groups.

Exclusion criteria

Exclusion criteria: • Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, large body tattoos) • Contraindications for contrast agent Gadovist (renal failure) as determined by the estimated Glomular Filtration Rate eGFR

Design outcomes

Primary

Measure	Time frame
The main study measures are blood brain barrier permeability as measured by T1-weighted dynamic contrast MRI; and cerebral perfusion as measured by Arterial Spin Labeling MRI.	—

Countries

Netherlands

Outcome results